ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research

Sep 22, 2026

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC

Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence

DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.

Why this award matters

NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.

"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."

Patrick Smale, Co-founder and Chief Executive Officer

"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."

Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator

"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."

Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member

The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.

Important regulatory context

ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.

About ClearSight Therapeutics


ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.

NIH funding acknowledgment

Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media contact

Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761

Contact
Patrick Smale
***@clearsighttx.com

Photos: (Click photo to enlarge)




Source: ClearSight Therapeutics, Inc.

Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source

Press release distribution by PRLog

MORE NEWS

The uncomfortable truth about aquariums

Sep 22, 2026

The uncomfortable truth about aquariums

Young visitors watch the beluga whales at L'Oceanogràfic in Valencia, Spain. | Miguel Candela/SOPA Images/LightRocket via Getty Images This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here. Four beluga whales have died in a month at one of America’s top-rated aquariums — a tragic development and, arguably, a reason to revisit the ethics of zoos. (More on that in just a minute.) The latest cetacean casualty, a 26-year-old female named Osiris, died at Chicago’s Shedd Aquarium yesterday. She follows 34-year-old Beethoven, a longtime resident of the aquarium, as well as 20-year-old Rain and 23-year-old Peekachu, who died in late August and early September.    Osiris, Rain and Peekachu were all part of the Marineland diaspora: a group of four dolphins and 30 beluga whales that rescuers have worked to relocate since the 2024 closure of a scandal-plagued theme park in Niagara Falls, Canada. This summer, the animals were successfully transferred to aquariums and marine parks in the US and Spain. That was a frankly incredible undertaking involving padded shipping containers, a police-escorted convoy and a chartered plane.  But in some regards, the international flight wasn’t even the hardest part of the whales’ journeys. Some of the animals have struggled to thrive in their new environments — even when those environments are state-of-the-art, like Shedd.  In a blog post announcing Osiris’s death, the aquarium noted that its rescued whales had been under 24-hour supervision and receiving intensive, specialized care. The aquarium is still investigating the cause of death for all four whales.  Go a little deeper View Link Believe me when I tell you that it gives me no pleasure to write the following paragraphs. I really love aquariums. In fact, as a kid, I grew up visiting the now-shuttered and much-maligned Marineland.  But incidents like these back-to-back deaths should prompt us all to ask ourselves who aquariums and zoos are actually for. And the answer, I regret to tell you, is frequently not “the animals” — though zoos and aquariums have, since the mid-20th century, marketed themselves as both tourist attractions and important players in wildlife education and conservation.   As my colleague Kenny Torrella writes, these institutions and their defenders argue they protect animals in three ways: first, by raising money for wildlife conservation projects; second, by helping to reintroduce vulnerable species back into the wild; and third, by inspiring visitors to take an interest in the environment. The Shedd Aquarium’s motto, for instance, is “For Love of Waterkind.”  It’s worth scrutinizing those purported virtues, however — even when prestigious and reputable institutions like Shedd are making them. On one hand, there is merit to the claim that zoos and aquariums fundraise for wildlife conservation: In 2022, the latest year for which data is available, one group of accredited zoos and aquariums spent more than a quarter of a billion dollars on habitat projects.  The evidence is thinner on the other points, though. It’s incredibly rare for aquariums and zoos to reintroduce endangered species back into the wild — that’s very difficult to do. And surveys of zoo and aquarium visitors show that merely seeing a wild animal in a tourist setting doesn’t generally galvanize people on matters of welfare or stewardship. Living in captivity in that tourist setting, however, can be stressful (or worse) for the animals themselves.  But what would a humane alternative look like? Even if zoos and aquariums stopped catching animals in the wild, that would still leave many thousands who are injured, orphaned, born in captivity, or otherwise accustomed to human care.  When it comes to whales, one nonprofit advocacy organization is already working on an alternative: a 110-acre coastal sanctuary for “retired” whales. That project, however, is still a long way from completion. And in the meantime, it’s up to consumers to decide whether the stated benefits of zoos and aquariums outweigh the potential harms to the animals they exhibit. One link for later ➨ Beware the trap of “moral perfection.” We should all endeavor to live lives that embody our values, sure. But if you never board a plane because you care about the climate, or you never take your kid to zoos because you read the arguments above, then you might end up with a smaller, less-lived life. And that’s no good, either.  Before you go… Did you know…that there have been “revolutionary” advancements in Alzheimer’s treatments in just the past five years? Two new drugs both markedly slow the progress of dementia. Today’s trivia: Geography time! What country is bordered by Chad to the east and Mali to the west? Hint: It is the second-largest landlocked African nation. (You can find this and other brain puzzles in Vox’s daily crossword. Look for the answer in tomorrow’s edition.) Yesterday’s trivia: Yesterday we asked you for the classic Broadway star who first sang hits including “There’s No Business Like Show Business.” That would be Ethel Merman, whom one biographer dubbed “the most successful musical comedy performer of her generation.”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

ABOUT US
Logo

We believe that information is the new age currency. Digital Press Network is your source for digital culture and innovation for the connected generation.

SUBSCRIBE
Copyright © 2015 - 2026 Digital Press Network. All Rights Reserved.